Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S.

Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the ...

「Dexcom G7」は、糖尿病のある方の日常の血糖マネジメントを容易にする新しいリアルタイムCGMで、この度、革新的な前製品（Dexcom G6）を、より小さく、使いやすく、かつ手ごろな価格でリデザインした点が高く評価され、2024年度グッドデザイン賞を受賞し ...

Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for adults with diabetes.

DexCom DXCM recently announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System has received ...

The device demonstrates a MARD of 8% and includes a 12-hour grace period and mobile app compatibility.

Users can go to dexcom.com/theft-check for information on how to determine if sensors are from the affected lots and what action to take. Users also can call Dexcom Customer Support in the United ...

Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support. The Apple Watch can make glucose checks quicker, but it does not measure blood ...

Diabeloop announced that its DBLG2 automated insulin delivery algorithm is now open for prescription with Dexcom G7 and .

Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...